Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio (QTTB) reported a director’s stock option grant on a Form 4. On 10/23/2025, the director acquired 53,521 stock options (Code A) with an exercise price of $2.80 per share, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual stockholder meeting, contingent on continued service. Following this transaction, the director beneficially owns 53,521 derivative securities, held directly. The price of the derivative security was listed as $0.00.
Q32 Bio (QTTB) reported a director stock option grant. On 10/23/2025, the reporting person received a stock option for 53,521 shares at an exercise price of $2.80 per share. Following the transaction, 53,521 derivative securities were beneficially owned directly.
The option vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service, and expires on 10/22/2035. The filing lists the grant as an acquisition.
Q32 Bio Inc. (QTTB) reported a director stock option grant on a Form 4. The filing lists a stock option (right to buy) for 53,521 shares at an exercise price of $2.80, dated 10/23/2025, with an expiration on 10/22/2035. The option acquisition is recorded at $0.00 for the derivative security.
Vesting occurs in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service. The ownership form is listed as Direct. A footnote states the reporting person is obligated, pursuant to an agreement, to transfer any securities or economic benefits from such awards to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure they are provided to OrbiMed Private Investments VII, LP.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. On 10/23/2025, the director was awarded 53,521 stock options at an exercise price of $2.80 per share. The options expire on 10/22/2035 and will vest in full on the earlier of 10/23/2026 or the company’s next annual stockholder meeting, subject to continued service. Following the grant, the director beneficially owns 53,521 derivative securities directly.
Q32 Bio (QTTB) reported a director equity grant on a Form 4. On 10/23/2025, the director was granted a stock option for 53,521 shares at an exercise price of $2.8 per share, expiring on 10/22/2035. The option vests in full upon the earlier of October 23, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continued service. Following the grant, 53,521 derivative securities were beneficially owned in direct form.
The filing notes that proceeds of any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and the Reporting Person disclaims ownership except to the extent of any pecuniary interest.
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options. The filing lists a Stock Option (Right to Buy) for 53,521 shares at an exercise price of $2.8 per share on 10/23/2025.
These options vest in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date. The option carries an expiration date of 10/22/2035 and is held directly. The grant price for the derivative security is shown as $0.00, consistent with option awards.
Q32 Bio Inc. (QTTB) reported an insider equity award on a Form 4. A director received a stock option grant covering 53,521 shares on 10/23/2025, with an exercise price of $2.80 per share and an expiration date of 10/22/2035. Ownership of the derivative security is listed as Direct.
The option vests in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the director’s continued service through that date. Following the reported transaction, the director beneficially owned 53,521 derivative securities.
Q32 Bio Inc. (QTTB) announced it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart for alopecia areata. The company disclosed the update via a press release titled “Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata,” furnished as Exhibit 99.1.
Jodie Pope Morrison, who serves as CEO and Director of Q32 Bio Inc. (QTTB), reported the automatic sale of 10,494 shares of common stock to satisfy tax withholding obligations from vested restricted stock units. The sales occurred on 08/26/2025 (deemed execution 08/27/2025) at a weighted average price reported as $1.801, with per-share prices ranging across two trading days from $1.73 to $1.96. Following the transactions, the reporting person beneficially owns 121,506 shares directly. The filing was signed by an attorney-in-fact on 08/28/2025.
Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette reported the sale of 2,990 shares of common stock on 08/26/2025 with a weighted average price of $1.801 per share. The filing states the sales were automatic to satisfy tax withholding obligations related to the vesting of restricted stock units and were not at the reporting person’s discretion. After the transaction, Ms. Violette directly beneficially owns 58,384 shares and indirectly holds 36,277 shares through Violette Holdings LLC, of which she is a manager and disclaims beneficial ownership except for any pecuniary interest.